Rapid Micro Biosystems, Inc.
Rapid Micro Biosystems (Nasdaq: RPID) develops and sells automated microbial quality control (MQC) solutions for pharmaceutical manufacturers, including producers of biologics, cell and gene therapies, vaccines and sterile injectables. Its Growth Direct platform combines automated testing systems, proprietary… From the company’s description.
Over the twelve months to Jun 30, 2026, Rapid Micro Biosystems, Inc. reported revenue of $35.18M, up 16.1% from a year earlier, and a net loss of $51.20M. Its operating margin was −141.5%, and operations used $40.06M in cash. In fiscal 2025, it reported revenue of $33.59M, up 19.7% from fiscal 2024, and a net loss of $47.12M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rapid Micro Biosystems, Inc. does
In the company’s own words
Rapid Micro Biosystems (Nasdaq: RPID) develops and sells automated microbial quality control (MQC) solutions for pharmaceutical manufacturers, including producers of biologics, cell and gene therapies, vaccines and sterile injectables. Its Growth Direct platform combines automated testing systems, proprietary consumables, software that connects with laboratory information management systems, and customer support and validation services. The platform automates sample handling, incubation and microbial detection, and supports environmental monitoring, water, in-process bioburden and sterility testing. Customers include pharmaceutical companies and other manufacturers with quality control testing needs; the company serves approximately 107 customer sites in 18 countries. It sells directly in North America, Europe and Asia-Pacific and uses distributors in some territories. MilliporeSigma also has global co-exclusive distribution rights for specified industrial quality control applications. Rapid Micro Biosystems placed 190 systems and sold approximately 9 million consumables globally, and its fiscal 2025 revenue was [not stated in the provided text]. Its website is www.rapidmicrobio.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1380106
- SIC
- 3826
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rapid Micro Biosystems, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rapid Micro Biosystems, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rapid Micro Biosystems, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rapid Micro Biosystems, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rapid Micro Biosystems, Inc.'s last four quarterly filings that the numbers alone won't show?”